MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze UTHR →
    • FindStock Picks / Stock Screener
    • Value · UTHRIntrinsic Value Calculator
    • Invest · UTHRInvestment Case
    • Hold · UTHR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
UTHR stock logo

UTHR

United Therapeutics Corporation

$554.73
-4.37
 (-0.78%)
Exchange:  NASDAQ
Market Cap:  23.625B
Shares Outstanding:  44.3M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Martine A. Rothblatt
Full Time Employees:  1400
Address: 
1040 Spring Street
Silver Spring
MD
20910
US
Website:  https://www.unither.com
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company’s current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso’s efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
UTUTHR logoUTHRUnited Therapeutics Corporation23.6B19.422.516.8%
ININCY logoINCYIncyte Corporation23.4B54.636.26.0%
BNBNTX logoBNTXBioNTech SE20.1B——-8.3%
ALALNY logoALNYAlnylam Pharmaceuticals, Inc.19.3B7.17.115.4%
ROROIV logoROIVRoivant Sciences Ltd.28.0B——-11.8%
ASASND logoASNDAscendis Pharma A/S16.6B16.215.411.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/04 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,327,5002,877,4003,182,700
Gross Profit2,070,0002,567,7002,798,300
EBITDA1,386,8001,654,4001,819,000
Operating Income1,184,9001,377,0001,517,200
Net Income984,8001,195,1001,334,700

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets7,167,0007,364,0007,880,000
Total Liabilities1,182,200920,000783,800
Total Stockholders Equity5,984,8006,444,0007,096,200
Total Debt700,000300,0000
Cash and Cash Equivalents1,207,7001,697,2001,557,100

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow978,0001,327,1001,561,200
Capital Expenditure-230,400-246,500-520,500
Free Cash Flow747,6001,080,6001,040,700
Net Income984,8001,195,1001,334,700
Net Change in Cash246,500489,500-140,100

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,294,901.475Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)6,575,793.870Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)5,910,932.786Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,101,308.427Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)3,989,035.464Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,528,251.017Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)2,121,863.227Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,813,287.287Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)2,454,396.051Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,255,114.791Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,558,740.269Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,401,140.173Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)51.240Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)58.730Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)44.300Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.877B  ?P/S
 (TTM)
: 
7.41
?Net Income
 (TTM)
: 
1.195B  ?P/E
 (TTM)
: 
19.42
?Enterprise Value
 (TTM)
: 
22.436B  ?EV/FCF
 (TTM)
: 
25.87
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
19.18%  ?ROIC
 (TTM)
: 
16.83%
?Net Debt
 (TTM)
: 
-2.967B  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
3.77  ?Current Ratio
 (TTM)
: 
4.61

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
22.50Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates UTHR intrinsic value between $632.41 – $644.51 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate UTHR Intrinsic Value

Common questions about UTHR valuation

Is United Therapeutics Corporation (UTHR) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for United Therapeutics Corporation (UTHR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is UTHR a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether UTHR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is UTHR’s P/E ratio?

You can see UTHR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for UTHR?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is UTHR a good long-term investment?

Whether UTHR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for United Therapeutics Corporation

  • United Therapeutics Corporation intrinsic value calculatorEstimate what the business is worth
  • United Therapeutics Corporation 5-year outlookWhat has to go right, and what could go wrong
UTHR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.78
MarketSnap

Trading Metrics:

Open: 559.36   Previous Close: 559.1
Day Low: 551.51   Day High: 563.12
Year Low: 455.63   Year High: 614.23
Price Avg 50: 548.85   Price Avg 200: 539.47
Volume: 355161   Average Volume: 643763

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
17-11-2026 14:03
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
16-11-2026 22:12
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC
16-11-2026 04:01
5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call
04-11-2026 17:15
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
04-11-2026 13:44
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
04-11-2026 06:30
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze UTHR →
    • FindStock Picks / Stock Screener
    • Value · UTHRIntrinsic Value Calculator
    • Invest · UTHRInvestment Case
    • Hold · UTHR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.